Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2016

Clark Chen's Biography



Clark Chen, Co-Director, University of California-San Diego

Dr. Clark Chen is a neurosurgeon with dedicated interest in oncology and a leader in the study of DNA repair and genetic alterations in brain tumors and in biomarker development. He received his B.S. in biology from Stanford University, his M.S. in epidemiology from Columbia University, and his M.D., Ph.D. from Harvard Medical School. He subsequently completed his neurosurgery training at the Massachusetts General Hospital, including a clinical fellowship in radiosurgery and a second fellowship on stereotactic neurosurgery. In his thesis work, Dr. Chen studied under Dr. Richard Kolodner to understand how cells maintain chromosomal stability. He then carried out his post-doctoral work with Dr. Alan D’Andrea at the Dana Farber Cancer Institute to understand the pertinence of chromosomal stability in glioblastoma. During this time, he collaborated closely with Xandra Breakfield to study Extracellular Vesicles (EVs) as a biomarker platform. He currently serves as the chief of stereotactic and radiosurgery and the Vice-Chairman of Neurosurgery at the University of California, San Diego. Dr. Chen is an NIH funded investigator and the recipient of several highly competitive research awards including: the Damon Runyon Fellowship Award, the Burroughs Wellcome Foundation Career Award in Medical Sciences, the Sontag Foundation Distinguished Scientist Award, the Doris Duke Foundation Clinical Scientist Award, and the Forbeck Scholar award. His current work focuses on the mechanisms of governing glioblastoma tumorigenicity, glioblastoma resistance to DNA damaging agents, and the development of predictive and prognostic glioblastoma biomarkers.

Clark Chen Image

CSF microRNA Profile as a Liquid Biopsy Platform to Assess Glioblastoma Tumor Burden

Tuesday, 22 March 2016 at 10:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Glioblastoma is the most common form of primary brain neoplasm and remains one of the deadliest of human cancers.  Clinical care for glioblastoma patients is largely limited by the absence of biomarker for assessment of tumor burden or therapeutic response. The discovery that glioblastoma cells secrete extra-cellular vesicles (EVs) containing tumor specific genetic material has opened a new platform for biomarker development.  These EVs transgress anatomic compartments and can be detected in clinical bio-fluids. The EVs shelter the tumor-specific genetic material from the extracellular environment that is replete with RNAses and preserve the integrity of these materials. Importantly, the genetic materials within EVs appear highly enriched for RNAs in the size range of microRNAs (miRNAs). The talk will focus on using cerebrospinal fluid (CSF) derived exosomal miRNA signature as a liquid biopsy platform for assessing glioblastoma tumor burden. Issues pertaining to vesicle quantitation, normalization, optimal specimen storage condition, and influence of microenvironment will be discussed.


Add to Calendar ▼2016-03-21 00:00:002016-03-22 00:00:00Europe/LondonCirculating Biomarkers World Congress 2016Circulating Biomarkers World Congress 2016 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com